デフォルト表紙
市場調査レポート
商品コード
1006300

ジェネリック注射剤の世界市場:分子タイプ別、製品タイプ別、流通チャネル別、投与経路別、アプリケーション別、地域別の、市場規模調査と予測(2020年~2027年)

Global Generic Injectable Market Size study, by Product type by Molecule Type by Application by Route of Administration by Distribution channel and Regional Forecasts 2020-2027.

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
ジェネリック注射剤の世界市場:分子タイプ別、製品タイプ別、流通チャネル別、投与経路別、アプリケーション別、地域別の、市場規模調査と予測(2020年~2027年)
出版日: 2021年05月03日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のジェネリック注射剤の市場規模は2019年に約307億2,000万米ドルとなり、2020年~2027年の予測期間中に10%以上の健全な成長率で成長すると予想されます。

ジェネリック注射剤は、ブランドの注射剤と生物学的に同等であり、医薬品の特許の下で保護されていません。有効成分、用量、強度、一貫性、種類が革新的な医薬品と同じであるため、安全で効率的です。ジェネリック注射剤は製造が困難ですが、研究開発期間は安価で短期間です。ジェネリック医薬品メーカーは、ブランド医薬品メーカーとは異なり、研究開発とマーケティングに何百万米ドルも投資する必要はありません。さらに、経口ジェネリック医薬品とは対照的に、ジェネリック注射剤業界への参入者数は少ないため、価格のデフレが緩和され、利益率が向上します。

慢性疾患の有病率の上昇により、ジェネリック注射剤の研究開発が進んでいます。 静脈内 (IV) および筋肉内 (IM) の薬物投与の人気は、緊急治療の代替手段の必要性に応えて成長しています。たとえば、インスリンは筋肉内(IM)投与するのが最適です。ジェネリック注射薬には、ライセンス取得の迅速化、生産パイプラインでのより多くの生物製剤、注射薬の配送に対する需要の増加など、さまざまな利点があります。ワクチン、モノクローナル抗体、ペプチド、免疫グロブリン、抗体の医薬品販売の機会は、費用対効果や健康上の成果の改善などの要因によって強化されています。現在、ジェネリック注射剤は、ブランドの同等品よりも費用対効果の高い薬として広く受け入れられています。

これらの動向の結果として、ジェネリック注射剤の採用率は増加しています。家族の病歴や肥満など、さまざまな原因が、先進国と新興諸国の両方で、糖尿病などの生活習慣病の有病率の増加に寄与しています。糖尿病の発生率が上昇すると、その治療に関連する医療費が増加します。WHOの統計によると、糖尿病の有病率は、患者数の増加により、2000年の1億1,700万人から、2030年には4億2,200万人に増加すると予測されています。糖尿病の有病率は、2000年にすべての年齢層で2.8%と計算され、2030年までに4.4%に増加すると予想されています。

さらに、ブランド品の特許の期限切れと新製品のリリース数の減少は、ジェネリック医薬品に利益をもたらし、業界の参加者と製品価格の成長につながりました。プレミアム医薬品の価格と比較して、ジェネリック注射剤は比較的安価であり、需要の伸びと純利益を大幅に押し上げます。ファイザーは2020年7月に、ミシガン州ポーテージにある無菌注射プラントの建設に約4億6,500万米ドルを投じることで合意に達したと発表しました。この成長は、国の企業評価の進展に遅れないようにするために、米国を拠点とする各資本課題に約50億米ドルを費やすという同社の戦略の一部です。

ただし、ジェネリック注射剤の製造には高度な機械が必要であり、どちらも出力前のバッチに対する厳しい登録および滅菌要件を満たす必要があります。固定資産の購入・貸与により、ランニングコストや負債比率が高くなります。さらに、生産プロセスだけでなく、処理、輸送、および配送中にも高いレベルの安全性を維持するというFDA要件の結果、コンプライアンスコストが大幅に高くなります。これは、2020年~2027年の予測期間にわたる市場の成長を妨げます。ただし、高分子製品の注射剤への拡大は、市場に有利な機会を提供する開発を促進しています。

当レポートではジェネリック注射剤の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、分子タイプ・製品タイプ・流通チャネル・投与経路・アプリケーション・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の定義と範囲

第3章 市場力学

  • 市場の影響分析(2018年~2027年)

第4章 業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論

第5章 製品タイプ別

  • 市場のスナップショット
  • パフォーマンス:潜在的な分析
  • 市場規模予測:2017年~2027年(10億米ドル単位)
  • サブセグメント分析
    • モノクローナル抗体
    • 免疫グロブリンジェネリック注射剤
    • インスリンジェネリック注射剤
    • 血液因子ジェネリック注射剤
    • ペプチド抗生物質ジェネリック注射剤
    • ワクチンジェネリック注射剤
    • 化学療法剤ジェネリック注射剤
    • その他

第6章 分子タイプ別

  • 市場のスナップショット
  • パフォーマンス:潜在的な分析
  • 市場規模予測:2017年~2027年(10億米ドル単位)
  • サブセグメント分析
    • 低分子ジェネリック注射剤
    • 大分子ジェネリック注射剤

第7章 アプリケーション別

  • 市場のスナップショット
  • パフォーマンス:潜在的な分析
  • 市場規模予測:2017年~2027年(10億米ドル単位)
  • サブセグメント分析
    • 腫瘍学
    • 感染症
    • 糖尿病
    • 血液疾患
    • 中枢神経系疾患
    • 心血管疾患
    • その他

第8章 投与経路別

  • 市場のスナップショット
  • パフォーマンス:潜在的な分析
  • 市場規模予測:2017年~2027年(10億米ドル単位)
  • サブセグメント分析
    • 静脈(IV)ジェネリック注射剤
    • 筋肉内(IM)ジェネリック注射剤
    • 皮下(SC)ジェネリック注射剤

第9章 流通チャネル別

  • 市場のスナップショット
  • パフォーマンス:潜在的な分析
  • 市場規模予測:2017年~2027年(10億米ドル単位)
  • サブセグメント分析
    • 病院薬局
    • 小売薬局
    • ドラッグストア
    • オンライン薬局

第10章 地域別

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第11章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Samsung Biologics Co Ltd
    • Aurobindo Pharma Limited
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Merck & Co. Inc.
    • Cipla Ltd
    • Pfizer Inc
    • Fresenius Kabi
    • Sanofi S.A
    • AstraZeneca Plc

第12章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Generic Injectable market, report scope
  • TABLE 2. Global Generic Injectable market estimates & forecasts by Region 2017-2027 (USD Billion)
  • TABLE 3. Global Generic Injectable market estimates & forecasts by Product Type 2017-2027 (USD Billion)
  • TABLE 4. Global Generic Injectable market estimates & forecasts by Molecule Type 2017-2027 (USD Billion)
  • TABLE 5. Global Generic Injectable market estimates & forecasts by Application 2017-2027 (USD Billion)
  • TABLE 6. Global Generic Injectable market estimates & forecasts by Route of Administration 2017-2027 (USD Billion)
  • TABLE 7. Global Generic Injectable market estimates & forecasts by Distribution Channel 2017-2027 (USD Billion)
  • TABLE 8. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 9. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 10. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 11. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 12. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 13. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 14. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 15. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 16. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 17. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 18. U.S. Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 19. U.S. Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 20. U.S. Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 21. Canada Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 22. Canada Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 23. Canada Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 24. UK Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 25. UK Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 26. UK Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 27. Germany Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 28. Germany Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 29. Germany Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 30. RoE Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 31. RoE Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 32. RoE Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 33. China Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 34. China Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 35. China Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 36. India Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 37. India Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 38. India Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 39. Japan Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 40. Japan Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 41. Japan Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 42. RoAPAC Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 43. RoAPAC Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 44. RoAPAC Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 45. Brazil Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 46. Brazil Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 47. Brazil Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 48. Mexico Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 49. Mexico Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 50. Mexico Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 51. RoLA Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 52. RoLA Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 53. RoLA Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 54. Row Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 55. Row Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 56. Row Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 57. List of secondary sources, used in the study of global Generic Injectable market
  • TABLE 58. List of primary sources, used in the study of global Generic Injectable market
  • TABLE 59. Years considered for the study
  • TABLE 60. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Generic Injectable market, research methodology
  • FIG 2. Global Generic Injectable market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Generic Injectable market, key trends 2019
  • FIG 5. Global Generic Injectable market, growth prospects 2020-2027
  • FIG 6. Global Generic Injectable market, porters 5 force model
  • FIG 7. Global Generic Injectable market, pest analysis
  • FIG 8. Global Generic Injectable market, value chain analysis
  • FIG 9. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 10. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 11. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 12. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 13. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 14. Global Generic Injectable market, regional snapshot 2017 & 2027
  • FIG 15. North America Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 16. Europe Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 17. Asia pacific Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 18. Latin America Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 19. Global Generic Injectable market, company market share analysis (2019)
目次

Global Generic Injectable Market is valued approximately USD 30.72 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10 % over the forecast period 2020-2027. Generic injectables are bioequivalents of branded injectables and are not secured under medication patents. Since they have the same active ingredient, dose, strength, consistency, and type as the innovator drugs, they are both safe and efficient. While generic injectables are more difficult to manufacture, their research and development period is less expensive and shorter. Generic drug makers, unlike branded drug producers, do not need to invest millions of dollars in R&D and marketing. Furthermore, as opposed to oral generics, the number of entrants in the generic injectables industry is smaller, resulting in less price deflation and greater profit margins. The rising prevalence of chronic diseases has prompted developments in generic injectables research and development. The popularity of intravenous (IV) and intramuscular (IM) drug administration has grown in response to the need for urgent care alternatives. Insulin, for example, is best administered intramuscularly (IM). Generic injectable medicines have a range of benefits, including quicker licenses, more biologic medications in production pipelines, and a greater demand for injectable medication delivery. Drug sales opportunities for vaccinations, monoclonal antibodies, peptides, immunoglobulins, and antibodies are being bolstered by factors such as cost-effectiveness and improved health outcomes. Generic injectables are now becoming more widely accepted as more cost-effective drugs than their branded counterparts. Adoption rates for generic injectables are increasing as a result of these trends. A variety of causes, including family medical history, obesity, among others, are contributing to an increase in the prevalence of lifestyle-related diseases such as diabetes in both developed and developing countries. The rising incidence of diabetes raises medical costs associated with its treatment. According to WHO statistics, the prevalence of diabetes is projected to grow from 117 million in 2000 to 422.0 million in 2030, owing to an increase in patient numbers. Diabetes prevalence was calculated to be 2.8 percent in all age ranges in 2000, and is expected to increase to 4.4 percent by 2030. Additionally, the expiration of branded item patents and a decrease in the number of new product releases have benefited generic drugs and led to the growth of industry participants and product prices. As compared to the prices of premium drugs, generic injectables are comparatively inexpensive, giving a substantial boost to demand growth and still the net profits. Pfizer announced in July 2020 that it had reached an agreement to commit about US$ 465 million to the construction of a sterile injectable plant in Portage, Michigan. This growth is part of the company's strategy to spend about $5 billion in each U.S.-based capital challenge in order to keep up with developments in the country's corporate evaluation. However, manufacturing generic injectables necessitates sophisticated machinery, both of which must meet stringent registration and sterilisation requirements for - batch prior to output. Owing to the purchase/rent-to-lease of fixed assets, which results in high running expenses and debt ratios. Furthermore, compliance costs are considerably higher as a result of FDA requirements that high levels of safety be maintained not only throughout the production process, but also during processing, transportation, and delivery. This impedes the growth of the market over the forecast period of 2020-2027. Although, the expansion of large molecule products into injectables are fueling developments presenting a lucrative opportunity for the market.

The main regions of Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical study of the global Generic Injectable market. North America is the leading region across the world in terms of market share owing to the well-established infrastructure and rising R&D expenditure. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate over the forecast period 2020-2027. Factors such as growth of government spending in pharmaceutical sectors would create lucrative growth prospects for the Generic Injectable market across Asia-Pacific region.

Major market player included in this report are:

Samsung Biologics Co Ltd

Aurobindo Pharma Limited

Sun Pharmaceutical Industries Ltd.

Novartis AG

Merck & Co. Inc.

Cipla Ltd

Pfizer Inc

Fresenius Kabi

Sanofi S.A

AstraZeneca Plc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product type:

Monoclonal Antibodies

Immunoglobulin Generic injectable

Insulin Generic injectable

Blood Factors Generic injectable

Peptide Antibiotics Generic injectable

Vaccines Generic injectable

Chemotherapy Agents Generic injectable

Others

By Molecule Type:

Small Molecule Generic injectable

Large Molecule Generic injectable

By Application:

Oncology

Infectious Diseases

Diabetes

Blood Disorders

CNS Diseases

Cardiovascular Diseases

Others

By Route of Administration:

Intravenous (IV) Generic injectable

Intramuscular (IM) Generic injectable

Subcutaneous (SC) Generic injectable

By Distribution channel:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Generic Injectable Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Generic Injectable Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Generic Injectable Market, by Product Type, 2018-2027 (USD Billion)
    • 1.2.3. Generic Injectable Market, by Molecule Type, 2018-2027 (USD Billion)
    • 1.2.4. Generic Injectable Market, by Application, 2018-2027 (USD Billion)
    • 1.2.5. Generic Injectable Market, by Route of Administration, 2018-2027 (USD Billion)
    • 1.2.6. Generic Injectable Market, by Distribution Channel, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Generic Injectable Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Generic Injectable Market Dynamics

  • 3.1. Generic Injectable Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of chronic diseases
      • 3.1.1.2. The expiration of branded item patents and a decrease in the number of new product releases
    • 3.1.2. Market Challenges
      • 3.1.2.1. Complex manufacturing of generic injectables
      • 3.1.2.2. Rising stringent regulation
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Expansion of large molecule products into injectables
      • 3.1.3.2. Investments on manufacturing capabilities by emerging countries

Chapter 4. Global Generic Injectable Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Generic Injectable Market, by Product Type

  • 5.1. Market Snapshot
  • 5.2. Global Generic Injectable Market by Product Type, Performance - Potential Analysis
  • 5.3. Global Generic Injectable Market Estimates & Forecasts by Product Type 2017-2027 (USD Billion)
  • 5.4. Generic Injectable Market, Sub Segment Analysis
    • 5.4.1. Monoclonal Antibodies
    • 5.4.2. Immunoglobulin Generic injectable
    • 5.4.3. Insulin Generic injectable
    • 5.4.4. Blood Factors Generic injectable
    • 5.4.5. Peptide Antibiotics Generic injectable
    • 5.4.6. Vaccines Generic injectable
    • 5.4.7. Chemotherapy Agents Generic injectable
    • 5.4.8. Others

Chapter 6. Global Generic Injectable Market, by Molecule Type

  • 6.1. Market Snapshot
  • 6.2. Global Generic Injectable Market by Molecule Type, Performance - Potential Analysis
  • 6.3. Global Generic Injectable Market Estimates & Forecasts by Molecule Type 2017-2027 (USD Billion)
  • 6.4. Generic Injectable Market, Sub Segment Analysis
    • 6.4.1. Small Molecule Generic injectable
    • 6.4.2. Large Molecule Generic injectable

Chapter 7. Global Generic Injectable Market, by Application

  • 7.1. Market Snapshot
  • 7.2. Global Generic Injectable Market by Application, Performance - Potential Analysis
  • 7.3. Global Generic Injectable Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
  • 7.4. Generic Injectable Market, Sub Segment Analysis
    • 7.4.1. Oncology
    • 7.4.2. Infectious Diseases
    • 7.4.3. Diabetes
    • 7.4.4. Blood Disorders
    • 7.4.5. CNS Diseases
    • 7.4.6. Cardiovascular Diseases
    • 7.4.7. Others

Chapter 8. Global Generic Injectable Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Generic Injectable Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Generic Injectable Market Estimates & Forecasts by Route of Administration 2017-2027 (USD Billion)
  • 8.4. Generic Injectable Market, Sub Segment Analysis
    • 8.4.1. Intravenous (IV) Generic injectable
    • 8.4.2. Intramuscular (IM) Generic injectable
    • 8.4.3. Subcutaneous (SC) Generic injectable

Chapter 9. Global Generic Injectable Market, by Distribution Channel

  • 9.1. Market Snapshot
  • 9.2. Global Generic Injectable Market by Distribution Channel, Performance - Potential Analysis
  • 9.3. Global Generic Injectable Market Estimates & Forecasts by Distribution Channel 2017-2027 (USD Billion)
  • 9.4. Generic Injectable Market, Sub Segment Analysis
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Drug Stores
    • 9.4.4. Online Pharmacies

Chapter 10. Global Generic Injectable Market, Regional Analysis

  • 10.1. Generic Injectable Market, Regional Market Snapshot
  • 10.2. North America Generic Injectable Market
    • 10.2.1. U.S. Generic Injectable Market
      • 10.2.1.1. Product Type breakdown estimates & forecasts, 2017-2027
      • 10.2.1.2. Molecule Type breakdown estimates & forecasts, 2017-2027
      • 10.2.1.3. Application breakdown estimates & forecasts, 2017-2027
      • 10.2.1.4. Route of Administration breakdown estimates & forecasts, 2017-2027
      • 10.2.1.5. Distribution Channel breakdown estimates & forecasts, 2017-2027
    • 10.2.2. Canada Generic Injectable Market
  • 10.3. Europe Generic Injectable Market Snapshot
    • 10.3.1. U.K. Generic Injectable Market
    • 10.3.2. Germany Generic Injectable Market
    • 10.3.3. France Generic Injectable Market
    • 10.3.4. Spain Generic Injectable Market
    • 10.3.5. Italy Generic Injectable Market
    • 10.3.6. Rest of Europe Generic Injectable Market
  • 10.4. Asia-Pacific Generic Injectable Market Snapshot
    • 10.4.1. China Generic Injectable Market
    • 10.4.2. India Generic Injectable Market
    • 10.4.3. Japan Generic Injectable Market
    • 10.4.4. Australia Generic Injectable Market
    • 10.4.5. South Korea Generic Injectable Market
    • 10.4.6. Rest of Asia Pacific Generic Injectable Market
  • 10.5. Latin America Generic Injectable Market Snapshot
    • 10.5.1. Brazil Generic Injectable Market
    • 10.5.2. Mexico Generic Injectable Market
  • 10.6. Rest of The World Generic Injectable Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Samsung Biologics Co Ltd
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Aurobindo Pharma Limited
    • 11.2.3. Sun Pharmaceutical Industries Ltd.
    • 11.2.4. Novartis AG
    • 11.2.5. Merck & Co. Inc.
    • 11.2.6. Cipla Ltd
    • 11.2.7. Pfizer Inc
    • 11.2.8. Fresenius Kabi
    • 11.2.9. Sanofi S.A
    • 11.2.10. AstraZeneca Plc

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption